MRK/MRNA: ASCO: vaccine-PD1 similar to historic PD1 alone

New data from MRK/MRNA cancer vaccine at ASCO last week continues to suggest a large underperformance of Keytruda control arm, along with Keytruda+vaccine arm demonstrating similar performance to Keytruda monotherapy phase 3 trials. Detailed analysis on the newly ASCO published secondary endpoint demonstrates curve separation appears to be driven by differences...